Stephen McAndrew - Sonnet Biotherapeutics Senior Development
| SONN Stock | USD 2.57 0.06 2.28% |
Executive
Stephen McAndrew is Senior Development of Sonnet Biotherapeutics Holdings
| Age | 70 |
| Address | 100 Overlook Center, Princeton, NJ, United States, 08540 |
| Phone | 609 375 2227 |
| Web | https://www.sonnetbio.com |
Sonnet Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9693) % which means that it has lost $0.9693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6457) %, meaning that it created substantial loss on money invested by shareholders. Sonnet Biotherapeutics' management efficiency ratios could be used to measure how well Sonnet Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -1.72. In addition to that, Return On Capital Employed is likely to grow to -0.17. At this time, Sonnet Biotherapeutics' Other Assets are very stable compared to the past year. As of the 2nd of December 2024, Net Tangible Assets is likely to grow to about 9 M, while Total Assets are likely to drop about 28.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ronan JD | Lyra Therapeutics | 51 | |
| Robert MD | Lyra Therapeutics | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| MS MD | DiaMedica Therapeutics | 51 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Ambarish Shah | DiaMedica Therapeutics | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Ellie MD | Centessa Pharmaceuticals PLC | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| David Wambeke | DiaMedica Therapeutics | 40 | |
| Lorianne MD | DiaMedica Therapeutics | 63 | |
| Richard MD | Lyra Therapeutics | 61 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
Management Performance
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 |
Sonnet Biotherapeutics Leadership Team
Elected by the shareholders, the Sonnet Biotherapeutics' board of directors comprises two types of representatives: Sonnet Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sonnet. The board's role is to monitor Sonnet Biotherapeutics' management team and ensure that shareholders' interests are well served. Sonnet Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sonnet Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Manuel Dafonseca, Head Operations | ||
| CPA CPA, Controller Director | ||
| Stephen McAndrew, Senior Development | ||
| Gael Hedou, Chief Officer | ||
| John Cini, Chief CoFounder | ||
| MD FACP, Chief Officer | ||
| Pankaj Mohan, Chairman, Founder | ||
| Jay Cross, Chief Officer | ||
| Susan Dexter, Chief Officer |
Sonnet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sonnet Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (219.69) % | ||||
| Current Valuation | (1.25 M) | ||||
| Shares Outstanding | 837.66 K | ||||
| Shares Owned By Insiders | 4.22 % | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 35.2 K | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 39.42 X |
Pair Trading with Sonnet Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sonnet Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sonnet Stock
Moving against Sonnet Stock
| 0.77 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.76 | VCYT | Veracyte | PairCorr |
| 0.68 | VERA | Vera Therapeutics | PairCorr |
| 0.63 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.62 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Sonnet Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sonnet Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sonnet Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sonnet Biotherapeutics Holdings to buy it.
The correlation of Sonnet Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sonnet Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sonnet Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sonnet Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.